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This combined drug therapy may be at least as effective asMycophenolate mofetil combined with a cyclooxygenase-2
steroids but without the obvious nephrotoxicity of the latter.inhibitor ameliorates murine lupus nephritis.
Background. Approaches to the treatment of lupus nephritis
include immunosuppressants associated with anti-inflamma-
tory drugs, mainly steroids, which, however, cause major side NZB/W F1 hybrid mice spontaneously develop a se-
effects. Mycophenolate mofetil (MMF) has been described as
vere autoimmune disease reminiscent of human systemicbeing less toxic than conventional immunosuppressants, and
lupus erythematosus (SLE) [1, 2], whose cardinal featureit was effective in preventing progressive nephritis in lupus
is the formation of autoantibodies against nuclear andmice. Our study evaluated the therapeutic effect of MMF in
NZB/W F1 hybrid mice with established disease. We also exam- endogenous antigens, among which nucleosomes, DNA
ined the combination of MMF with a selective cyclooxygenase-2 complexed to histones, seem to be the most prominent
(COX-2) inhibitor, DFU, based on previous findings of exces- [3, 4]. In vivo, nucleosomes are generated by apoptosis,
sive renal production of COX-2-derived thromboxane A2 a process that appears disturbed in lupus. In conditions(TXA2) in lupus nephritis.
of insufficient removal of apoptotic cells, nucleosomesMethods. Four groups of NZB/W mice (N 30 each group),
act as autoantigens to drive a T-cell–dependent immunestarting at five months of age, were given daily by gavage the
following: vehicle, MMF 60 mg/kg, DFU 3 mg/kg, or MMF  response, whose critical components are nucleosome-
DFU. Fifteen mice for each group were used for the survival specific antibodies and nucleosome/IgG complexes [5].
studies, and the remaining mice were sacrificed at nine months. These bind to intrinsic constituents of the glomerular
Results. MMF or DFU alone partially delayed the onset basement membrane and promote inflammation.of proteinuria compared with vehicle. Combined therapy was
Extensive preclinical research has been devoted tosignificantly (P  0.05) more effective than single drugs. Ani-
discovering new interventions alternative to immuno-mal survival was partially ameliorated by MMF and signifi-
suppressants and steroids that, at least in the acute phasecantly improved by the drug combination in comparison with
the vehicle (P  0.005) and DFU alone (P  0.03). At nine of the disease, have excellent therapeutic effects and no
months, serum blood urea nitrogen (BUN) levels were lower major side effects in the long term [6]. Among modern
in all of the treated groups than in the vehicle group. Renal molecules that can modulate B-cell function, and thus
damage was also limited, but to a greater extent in mice given
limit the formation and deposition of immune com-the combined therapy. In untreated mice, renal COX-2 mRNA
plexes, is mycophenolate mofetil (MMF), an inhibitorexpression was up-regulated, and generation of TXB2, the sta-
of purine metabolism [7]. MMF is more selective thanble breakdown product of TXA2, increased. DFU prevented
the abnormal renal TXB2 production, confirming the COX-2 azathioprine in inhibiting B- and T-cell proliferation by
origin of this eicosanoid, whereas renal 6-keto-PGF1 and pros- the action of its hydrolysis product, mycophenolic acid.
taglandin E2 (PGE2) were not affected substantially. By blocking monophosphate dehydrogenase, mycophe-
Conclusions. These results offer a strong case for exploring nolic acid inhibits de novo purine synthesis in lympho-the possibility that in humans MMF combined with COX-2
cytes, and by the same mechanism, it also prevents theinhibitors has a role in the treatment options for lupus nephritis.
generation of cytotoxic T cells and down-regulates adhe-
sion molecule expression on lymphocytes, which impairs
their binding to vascular endothelial cells [7]. MMF hasKey words: nephrotoxicity, immunosuppression, anti-inflammatory,
DFU, progressive nephritis, autoimmune disease, inflammation. been successfully used in renal transplantation [8–10] as
well as in several autoimmune diseases of humansReceived for publication December 28, 2000
[11–13], and confers remarkable renoprotection whenand in revised form March 2, 2001
Accepted for publication March 8, 2001 administered in lupus mice early before the onset of
renal disease [14, 15]. 2001 by the International Society of Nephrology
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In lupus nephritis, glomerular subendothelial and mes- Given previous data that MMF is beneficial in experi-
mental lupus when administered as a preventive treat-angial immune deposits evoke an inflammatory reaction
caused by the recruitment of mononuclear circulating ment [14, 15], here we first sought to establish if MMF
also could be used to cure the disease. Additionally,cells [4, 6]. Renal resident and infiltrating cells perpetu-
ate immune complex-mediated injury by releasing pro- considering the rationale presented earlier in this article
in favor of COX-2 inhibition, we evaluated the effectsinflammatory and chemoattractant molecules, which am-
plify the inflammatory process [16, 17]. of COX-2 inhibitor in established disease as compared
to MMF. Finally, we wanted to explore whether theThromboxane A2 (TXA2) has been implicated as a
major mediator in that in mice as well as in patients with combination of MMF with a COX-2 blocker could offer
a greater renoprotection than each drug alone.active lupus nephritis, renal TXA2 production increased
and correlated with both proteinuria and the severity of
renal pathological changes [18, 19]. Long-term pharma-
METHODS
cological blocking of TXA2 synthesis limited proteinuria
Experimental designas well as renal lesions and prolonged survival in mice
[20]. Similarly, in human lupus, acute administration of NZB/W F1 female mice (Harlan Italy srl, Milano, It-
aly), two months of age at the start of the experiment,a selective TXA2 receptor antagonist improved renal
function, as documented by increased inulin as well as were used. Animal care and treatment were conducted
in conformity with the institutional guidelines that arethe para-aminohippurate clearance rate [21].
The key enzyme in TXA2 generation is the prostaglan- in compliance with national (D.L. n.116, G.U., Suppl 40,
18 Febbraio 1992, Circolare No. 8, G.U., 14 Luglio 1994)din-forming enzyme cyclooxygenase (COX), which con-
sists of two isoforms: constitutive COX-1, mediating cy- and international laws and policies (EEC Council Direc-
tive 86/609, OJL 358, Dec 1987; NIH Guide for the Caretoprotection of the gastric mucosa, regulation of renal
blood flow and platelet aggregation, and inducible COX-2, and Use of Laboratory Animals, U.S. National Research
Council, 1996). Animals were housed in a constant tem-expressed in the context of inflammation mainly in mono-
nuclear leukocytes, endothelial cells, and mesangial cells perature room with a 12-hour dark/12-hour light cycle
and were fed a standard diet.[22]. COX-2 has been found to play a role in the regula-
tion of renin production in the kidney [23–25]. In renal To assess renal COX-1 and COX-2 gene expression,
five NZB/W mice were sacrificed at two, five, and ninecortex, COX-2 expression is localized in the macula de-
nsa and the cortical thick ascending limb of Henle months of age. Kidneys were processed for total RNA
preparation and Northern blot analysis. Kidneys from(cTALH) cells, and studies have demonstrated an in-
crease of COX-2 mRNA and protein in high renin states nine-month-old normal CD-1 mice (Charles River Italia,
Calco, Italy) were processed in parallel.such as salt restriction and angiotensin-converting en-
zyme inhibition. The stimulation of the renin systems in Pilot study. A pilot study was performed in 18 normal
mice to assess the dose of the COX-2 inhibitor, 5,5-these conditions was substantially attenuated by selective
COX-2 inhibitors. dimethyl-3-(3-fluorophenyl)-4-(4methylsulphonyl)phenyl-
2(5H)-furanone (DFU; Merck Sharp & Dohme, Rome,Our prior study described an up-regulation of COX-2
isoenzyme in circulating monocytes and kidney of pa- Italy) [30], that would be sufficient to inhibit COX-2
activity and yet leave COX-1 unaltered. Mice were giventients with active lupus nephritis as compared with sub-
jects in whom the disease was no longer active and to vehicle orally (0.5% carboxymethylcellulose; Sigma Chem-
ical Co., St. Louis, MO, USA) or DFU at the doses ofhealthy controls, in the face of unchanged COX-1 expres-
sion, disclosing a novel pathway of inflammatory injury 3 and 10 mg/kg/day for four days. The dose of 3 mg/kg
was chosen on the basis of a previous published studyin lupus nephritis [26]. In those patients, COX-2 staining
in glomeruli colocalized with the macrophage marker in the rat [30]. Animals were sacrificed four hours after
last drug administration. COX-2 activity was evaluatedCD 68, suggesting that monocytes infiltrating the glomer-
uli would be the cellular source of TXA2 in the kidney. by measuring COX-2–dependent formation of PGE2 in
plasma obtained from heparinized blood incubated withIt follows that selective inhibitors of COX-2 [27], by
blocking COX-2–derived TXA2 synthesis, might help re- aspirin (50 g/mL; A.C.E.F., Piacenza, Italy) to inhibit
COX-1 activity and stimulated with lipopolysaccharideduce renal inflammation in experimental lupus nephritis.
This possibility is in keeping with data showing that renal (LPS; 20 g/mL; Escherichia coli serotype 026:B6; Sigma
Aldrich, Milan, Italy) to induce COX-2. COX-1 activitycortical COX-2 expression was selectively up-regulated
in a model of progressive renal inflammation and injury was assessed by measuring serum TXB2 after whole blood
clotting: TXA2 is the major product of platelet COX-1,following subtotal nephrectomy in the rat [28], and that
chronic treatment with a COX-2 inhibitor decreased pro- and inhibition of serum TXB2, its inactive hydrolysis
product, reflects the inhibition of COX-1. Both proceduresteinuria and led to significant preservation of glomerular
structure and function in this setting [29]. have been previously described by McAdam et al [31].
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Chronic study. For the chronic study, NZB/W mice standard of equal loading of the samples on the mem-
brane. COX-1 and COX-2 mRNA optical densities werewere divided into four groups. Group 1 (N  30) was
given vehicle orally (0.5% carboxymethylcellulose). Group normalized to that of the constituently released GAPDH
gene expression.2 (N 30) was given the immunosuppressive agent MMF
orally (Roche Pharmaceuticals, Milano, Italy) as a daily
Proteinuria and renal functionadministration at the dose of 60 mg/kg [14]. Group 3 (N
30) was given the selective COX-2 inhibitor DFU orally Urinary protein concentration was determined by the
Coomassie blue G dye-binding assay with bovine serumat the dose of 3 mg/kg/day (on the basis of the pilot study).
Group 4 (N  30) was given MMF orally (60 mg/kg/ albumin as standard [34]. Renal function was assessed
as BUN on serum samples using an enzymatic UV Rateday) plus DFU (3 mg/kg/day). Treatments started at five
months, a time when immune complex deposition is ac- by Sincron CX-5 (Beckman, Fullerton, CA, USA). BUN
levels exceeding 30 mg/dL were considered abnormaltively taking place [1, 32, 33]. Fifteen animals for each
group were used for the survival studies, and the others (normal range in our laboratory: 14 to 29 mg/dL).
were sacrificed at nine months. Six additional NZB/W
Anti-DNA antibodiesmice sacrificed at two months of age were used as con-
trols. The levels of anti-dsDNA autoantibodies were eval-
uated by an enzyme-immunoassay (Diastat anti-ds DNABefore starting treatment, all mice were housed in
metabolic cages, and 24-hour urines were collected for kit; Bouty Laboratory, Milano, Italy) as described before
[33].determination of basal urinary protein excretion levels.
Baseline values of urinary protein excretion ranged from
Renal morphology0.8 to 3.9 mg/day. Thus, levels exceeding 4 mg/day during
the subsequent follow-up were considered abnormal. Light microscopy. Fragments of renal cortex were
fixed in Dubosq-Brazil, dehydrated in alcohol, and em-Urinary protein excretion was then measured every two
weeks. At sacrifice (9 months), blood was collected for bedded in paraffin. Sections (3 m) were stained with
hematoxylin and eosin, Masson’s trichrome, and periodicmeasurements of serum blood urea nitrogen (BUN) and
anti-DNA antibodies. Kidneys were taken for histologi- acid-Schiff’s reagent (PAS-stain). Glomerular intracapil-
lary hypercellularity was evaluated in a semiquantitativecal analysis by light microscopy. Measurements of renal
eicosanoid production in tissue homogenate (9 months) fashion by a scoring system from 0 to 3 (0  no hyper-
cellularity; 1  mild; 2  moderate; and 3  se-and urinary excretion of eicosanoids (months 2, 5, 8, and
9) were performed in mice of groups 1 and 2. The spleen vere). A single score was given for other changes based
on the percentages of total glomeruli involved with awas removed from animals of all groups, and analyses
of phenotype and release of TXB2, the stable hydrolysis lesion. Extracapillary proliferation was graded from 0 to
3 (0  no hypercellularity; 1  less than 25% ofproduct of TXA2, were performed.
glomeruli involved; 2  25 to 50% of glomeruli in-
RNA isolation and Northern blot analysis volved; and 3more than 50% of glomeruli involved).
Glomerular deposits were graded from 0 to 3 (0  noTotal RNA was isolated from mouse kidneys by the
guanidium isothiocyanate/cesium chloride procedure. deposits; 1 less than 25% of glomeruli involved; 2
25 to 50% of glomeruli involved; and 3  more thanFor mRNA preparation, total RNA of kidneys of each
group of NZB/W mice was pooled together. Poly (A) 50% of glomeruli involved). Tubular (atrophy, casts, and
dilation) and interstitial changes (fibrosis and inflamma-RNA was selected by oligo (dT)-cellulose column chro-
matography (mRNA separator; Clontech, Palo Alto, tion) were graded from 0 to 3 (0  no changes; 1 
changes affecting less than 25% of the sample; 2 CA, USA). Seven micrograms of mRNA were then frac-
tionated on 1.2% agarose gel and blotted onto synthetic changes affecting 25 to 50% of the sample; 3 changes
affecting more than 50% of the sample). At least 100membranes (GeneScreen Plus; New England Nuclear,
Boston, MA, USA). COX-1 mRNA was detected using glomeruli were examined for each biopsy. At least 10
fields per sample were examined at low magnificationa 1.1 kb fragment of human COX-1 cDNA (Cayman
Chemical Co., Ann Arbor, MI, USA), and COX-2 mRNA (10) for histologic scoring of the interstitium. All renal
biopsies were analyzed by the same pathologist, in awas detected using a 1.1-kb fragment of murine COX-2
cDNA (Cayman Chemical Co.). The DNA fragments single-blinded fashion.
Immunofluorescence. Studies were carried out onwere labeled with 32PdCTP by the random-primed
method. Membranes were hybridized as previously de- fresh frozen tissue. Sections 3 m thick were cut, fixed
in acetone, washed with phosphate buffer saline (PBS),scribed [26]. After washing, membranes were exposed
to x-ray film for autoradiography. Membranes were sub- pH 7.4, for 10 minutes, and stained with fluorescein iso-
thiocyanate conjugated to antibodies to mouse IgG andsequently probed with a glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) cDNA, taken as an internal C3 (N.L. Cappel Laboratories Inc., West Chester, PA,
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USA). Sections were rinsed in PBS, pH 7.4, for 45 min- ammonium chloride to remove the contaminating eryth-
rocytes. Cells were then resuspended in complete RPMIutes at room temperature and examined in a Leitz ortho-
mat microscope under ultraviolet light (Ernst Leitz, Wetz- 1640 medium (Life Technologies Italia, Milano, Italy)
supplemented with 10% fetal calf serum (FCS). Viablelar, Germany). Glomerular staining to different antibodies
was graded from 0 to 3 (0  no staining; 1  faint splenocytes were counted by trypan blue exclusion test.
An aliquot (1  106 splenocytes) was incubated for 60staining; 2  intense staining; and 3  very intense
staining). minutes at 37C in serum-free RPMI medium for the
assessment of TXB2 release.
Eicosanoid synthesis in renal tissue
Phenotypic analysis of splenocytesSixty milligrams of kidney tissues were finely and uni-
formly minced with a razor blade and gently pressed Cell surface phenotypic analysis was performed on
splenocytes (5  105) by flow cytometric analysis usingthrough a 140-mesh stainless steel sieve into 10 mL of
PBS. These suspensions were then centrifuged, and the the FACSsort (Becton Dickinson Co., Mountain View,
CA, USA). The following antibodies were used: anti-Igsupernatants were discarded. The pellets were resus-
pended in 2 mL Kreb’s-Ringer bicarbonate buffer, pH -chain (clone Hb58), anti-CD4 (clone GK1-5, Tib 207),
and anti-CD8 (clone 53-6,72, Tib 105). All of the antibod-7.4, and incubated at 37C for 30 minutes with constant
agitation. At the end of the incubation, the supernatants ies were from American Type Culture Collection (Rock-
ville, MD, USA) and were used as tissue culture superna-were removed and stored at 	20C for eicosanoid mea-
surement by radioimmunoassay (RIA). The pellets were tants. FITC-conjugated F(ab
)2 goat anti-rat IgG was
used as secondary antibody (Southern Biotechnologyresuspended in NaOH for protein determination by
Lowry method. Associates, Birmingham, AL, USA). To block Fc recep-
tor aspecific binding, a 30-minute preincubation with
Urinary excretion of eicosanoids PBS containing 5% mouse serum was performed. Cells
were then incubated with primary antibodies for 30 min-Urinary samples were extracted before RIA as pre-
viously described [35]. Briefly, urine was acidified to pH utes at 4C in PBS 5% FCS, washed twice, and incubated
with optimal concentration of the secondary antibody.3.5 and passed through a disposable (C18) column (Sep-
pak, Millipore, Milford, MA, USA) and eluted with ethyl- All stainings included negative controls from which the
primary antibodies were omitted. Light scattering pa-acetate. The elution fraction was dried and applied to
C8 column. Prostaglandin fractions were eluted with ben- rameters were set to exclude dead cells and debris.
zene:ethylacetate:methanol 60:40:20 for TXB2 and PGE2
Statistical analysisor benzene:ethylacetate:methanol 60:40:30 for 6-keto-
PGF1. The elution fraction was dried and frozen at	20 Data are expressed as mean  SE. Survival curves
were analyzed by log-rank test. Proteinuria data wereuntil assay.
analyzed by chi-square test or Fisher’s exact test as ap-
Radioimmunoassay propriate, followed by Bonferroni adjustment for multi-
ple comparisons. All the other parameters were analyzedThromboxane B2, 6-keto-PGF1, and PGE2 were mea-
sured by RIA [35] using specific antibodies. Briefly, anti- by Kruskal-Wallis test. Statistical significance was de-
fined as P  0.05.body anti-TXB2 (final concentration in the assay 1:300,000),
antibody anti-6-keto-PGF1 (final concentration 1:300,000),
and antibody anti-PGE2 (final concentration 1:100,000) RESULTS
were incubated for 18 hours at 4C with 2700 cpm of
Renal COX-1 and COX-2 mRNA expressiontritiated compound and with increasing amounts of unla-
in NZB/W micebeled eicosanoid (standard curves: from 1 to 100 pg/mL
for TXB2 and 6-keto-PGF1 and from 2 to 200 pg/mL for We evaluated whether in NZB/W mice the abnormal
renal synthesis of TXA2 was associated with altered ex-PGE2) or with samples. The bound antibody was sepa-
rated from the free ligand by adding 0.1 mL of human pression of COX isoforms [18]. COX-1 and COX-2 gene
expression was assessed by Northern blot analysis inprostaglandin-free plasma and 0.1 mL of a charcoal sus-
pension, then by centrifugation for 10 minutes at 500g at kidneys from lupus mice at two, five, and nine months
of age. Nine-month-old CD-1 mice were used as controls.4C. The smallest concentration that could be measured
with 95% confidence was 2 pg/mL. Intra-assay and inter- As shown in Figure 1, a band for COX-1 mRNA of
approximately 2.8 kb was present in renal tissue fromassay variability averaged 5 and 10%, respectively.
both NZB/W and control mice. There were no changes
Isolation of spleen cells in renal COX-1 mRNA during autoimmune disease. Hy-
bridization with a specific COX-2 cDNA probe showedSpleens were cut into small fragments, filtered through
a stainless steel screen, washed in PBS, and treated with a transcript of approximately 4.1 kb in all kidney samples.
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Fig. 1. Northern blots showing renal expres-
sion of cyclooxygenase-1 (COX-1; A) and
COX-2 (B) mRNA in NZB/W and CD-1 mice.
mRNA (7 g) obtained from pooled kidneys
at each time point was blotted into synthetic
membranes that were hybridized sequentially
with 32P-labeled human COX-1 or COX-2
and GAPDH cDNA probes. The optical den-
sity of the autoradiographic signals was quan-
titated and calculated as the ratio of COXs to
GAPDH mRNA. The mRNA levels at five
and nine months were calculated by assuming
the optical density of two months as unit.
In NZB/W mice at two and five months of age, transcript survival in the MMF group was 20%. An effect of DFU
treatment on lupus mice survival was evident until eightlevels were comparable to those of control animals. By
contrast, COX-2 mRNA was up-regulated in nine- months of age (% of survival, 75 vs. 53% of the vehicle
group). Starting from nine months of age, the DFU andmonth-old NZB/W mice with overt disease, with a three-
vehicle groups showed a similar mortality rate. Com-fold increase in the signal, as revealed by densitometric
bined administration of MMF with DFU significantlyanalysis. The finding of a selective increase in COX-2
prolonged the survival of lupus mice with respect toisoform provided us the rationale to treat NZB/W mice
vehicle (P  0.005) and DFU alone (P  0.03). Thus,with a COX-2 inhibitor.
at eight and nine months of age, 94 and 80% mice were
Pilot study alive (vs. 53 and 47% of vehicle group) and at 13 months,
when all NZB/W mice given vehicle died, 53% of miceUsing the preliminary data from the study performed
in normal mice, we selected a dose of the COX-2 inhibi- treated with the combined therapy still survived.
tor DFU that was sufficient to inhibit COX-2 activity
Effect of MMF, COX-2 inhibitor, and theirbut left COX-1 unaltered. COX-2 activity was evaluated
combination on proteinuria and renal functionby measuring COX-2–dependent formation of PGE2 in
A cumulative percentage of mice with heavy protein-plasma (Methods section). COX-1 activity was assessed
uria (4 mg/day) was evaluated at different stages of theby measuring serum TXB2. A complete inhibition of
disease in all of the experimental groups. As shown inPGE2 production, as compared with vehicle, was ob-
Figure 3, in the vehicle group the percentage of mice withserved after administration of both 3 and 10 mg/kg DFU.
proteinuria progressively increased over time. At theConversely, the serum TXB2 inhibition only achieved 25
end of the study (month 13, when the last animal in theto 30% inhibition in the same conditions. Thus, from
vehicle group died), the percentage of proteinuric micethese experiments we choose to use 3 mg/kg DFU for
was 93% (100% was not reached since one mouse diedthe chronic study.
at 10 months with proteinuria levels 4 mg/day). MMF
Chronic study or COX-2 inhibitor alone partially delayed the onset of
proteinuria compared to vehicle (% proteinuric mice,Effect of MMF, COX-2 inhibitor, and their combina-
tion on lupus mice survival. Figure 2 shows the survival month 7 was MMF, 20%; DFU, 8%; vehicle, 53%; month
8 was MMF, 53%; DFU, 50%; vehicle, 73%; month 9curves of NZB/W mice that from five months of age were
given vehicle, MMF, DFU, or the combined therapy. was MMF, 60%; DFU, 58%; vehicle, 87%). Combined
therapy significantly (P  0.05) prevented the develop-Treatment with MMF ameliorated survival so that at
eight and nine months of age, 93 and 67% of mice were ment of proteinuria with respect to vehicle and was also
significantly (P  0.05) more effective than single drugsalive as compared with 53 and 47% of vehicle group,
respectively. At 13 months, when 100% mortality was starting from month 9. Thus, in the group given MMF
plus DFU the percentage of mice with proteinuria atreached in the group given vehicle, the percentage of
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Fig. 4. Serum blood urea nitrogen (BUN) levels measured at nine
months in NZB/W mice treated with vehicle, MMF, DFU, or combined
therapy since five months of age. Controls were two-month-old NZB/W
mice. Values are expressed as mean  SE. P  0.05 vs. control; *P 
0.05 vs. vehicle.
Fig. 2. Survival rate in NZB/W mice given MMF (), the COX-2
inhibitor, DFU (), or their combination (MMF  DFU; ) since five
months of age, a time point that follows the onset of immune complex
trast, serum BUN levels were lower in all treated groups,deposition. Combined therapy significantly prolonged life survival in
respect to vehicle () and DFU alone. *P  0.005 vs. vehicle; §P  with values being within the range of control.
0.03 vs. DFU alone.
Effect of MMF, COX-2 inhibitor, and their
combination on anti-DNA antibodies
Serum levels of circulating anti-DNA antibodies mea-
sured in two-month-old NZB/W mice averaged 240.8
U/mL. At nine months, NZB/W mice given vehicle ex-
hibited significantly (P  0.05) increased levels of anti-
DNA antibodies (201  59 U/mL). MMF treatment had
no significant effect on autoantibody formation, with
levels averaging 210  93 U/mL. This finding is in line
with data from van Bruggen et al, showing no differences
between MMF-treated and control animals with regard
to autoantibody formation in the MRL/lpr mouse model
of lupus [15]. In our previous study in NZB/W mice
anti-DNA formation—as measured at eight months of
age—was prevented by MMF treatment that, however,
started at three months of age [14]. In the groups of
mice treated with the COX-2 inhibitor alone or with theFig. 3. Effects of vehicle (), MMF (), DFU (), and the combined
therapy (MMFDFU; ) on the cumulative percentage of proteinuric combined therapy, levels of anti-DNA antibodies were
mice at different ages. Treatments started at five months. Each point not affected by the treatment and averaged 199  48
reflects the current level of proteinuria in surviving mice as well as the
and 204  47 U/mL, respectively.last measurement in deceased mice. *P  0.05 vs. vehicle; #P  0.05
vs. MMF or DFU alone.
Effect of MMF, COX-2 inhibitor, and their
combination on renal morphology
Light microscopy analysis of kidneys from two-month-
seven, eight, and nine months was 0, 6, and 13%, respec- old NZB/W did not show significant changes. As shown
tively. At 13 months, only 6 out of 15 mice given the in Figure 5, at nine months, NZB/W mice given vehicle
combined therapy had developed proteinuria. revealed pronounced glomerular changes with endocapi-
Renal function, evaluated by serum BUN measure- llary hypercellularity associated with a focal extracapil-
ment at nine months, was significantly impaired in the lary proliferation. Immune type of deposits were de-
vehicle group compared to controls (2-month-old NZB/W), tected in the mesangium and on subendothelial aspect of
the glomerular basement membrane (GBM). Interstitialas reflected in elevation of BUN values (Fig. 4). In con-
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Fig. 5. Renal morphological parameters eval-
uated on biopsies taken at nine months of age
from NZB/W mice treated with vehicle (),
MMF ( ), DFU ( ) or combined therapy
(). Values are expressed as mean score 
SE. P  0.05, * P  0.01 vs. vehicle.
Table 1. IgG and C3 deposits in glomerular capillary loops ininflammation, fibrosis, and tubular damage were severe.
glomeruli of NZB/W mice at 9 months of age
Treatments with either MMF or DFU alone markedly
Groups IgG C3limited glomerular hypercellularity, immune deposits,
Vehicle 2.70.37 2.70.3and tubulointerstitial damage. With the combination of
MMF 0.90.4a 0.80.4aMMF and DFU, there was a trend toward a further
DFU 1.70.3 1.30.3
reduction in the severity of lesions. MMF  DFU 0.20.2ab 0.40.2a
By immunofluorescence, no significant deposits of IgG Results are mean score  SE. Abbreviations are: IgG, immunoglobin G;
MMF, mycophenolate mofetil; DFU, a COX-2 inhibitor.and C3 were detected in two-month-old NZB/W mice.
a P  0.05 vs. vehicleAt nine months, mice given vehicle had diffuse granular b P  0.05 vs. DFU
deposits of IgG and C3 in the mesangium and in the
glomerular capillary wall. Treatment with MMF led to
a significant decrease in the amount of IgG deposits
Effect of COX-2 inhibitor on renal eicosanoidin the glomerular capillary wall, compared with vehicle
production in NZB/W micegroup (Table 1). Less IgG deposits were also observed
in the mesangium, although not to a significant extent We assessed the effect of chronic treatment with the
(1.8  0.3 and 2.6  0.3 for MMF and vehicle-treated COX-2 inhibitor on eicosanoid production in renal tissue
mice, respectively). The pattern of C3 deposition was homogenate obtained from NZB/W mice at nine months
identical with significantly fewer C3 deposits in the glo- of age (Fig. 6). A significant increase in TXB2 production
merular capillary walls of MMF-treated mice (Table 1). was observed in NZB/W mice given vehicle compared
In mice treated with DFU, fewer IgG and C3 deposits with two-month-old NZB/W control mice. DFU treat-
were detected with respect to vehicle, but a statistical ment was associated with a normalization of the exagger-
significance was not reached (Table 1). In contrast, in ated synthesis of TXB2. Renal 6-keto-PGF1 and PGE2
mice given the combined therapy, IgG and C3 deposits production was not substantially modified by DFU. Con-
along the glomerular capillary wall were significantly less sistently, urinary excretion of eicosanoids, which likely
than in mice treated with vehicle and tended to be further reflects their renal synthesis, followed the same trend
decreased in respect to mice given MMF alone. Fewer (Fig. 7). Actually, in NZB/W mice given vehicle, the
IgG and C3 deposits also were observed to some extent urinary TXB2 excretion was significantly increased at
in the mesangium in the mice given the combined ther- eight and nine months of age as compared with values
obtained measuring the urines of the same animals atapy as compared to the vehicle-treated animals that were
still alive at this time point (IgG, 1.6  0.2 vs. 2.6  0.3; months 2 and 5. Treatment with DFU prevented such
an increase. Urinary 6-keto-PGF1 and PGE2 did notC3, 1.4  0.2 vs. 2.7  0.3, P  NS).
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change during the course of the disease, and they were
not affected by COX-2 administration.
Effect of MMF, COX-2 inhibitor, and their
combination on splenocyte count and
lymphocyte subset distribution
To study the effect of either MMF and DFU alone or
in a combination on lymphoid cell number and distribu-
tion, a total splenocyte count and lymphocyte subset
analysis were performed on spleen cells taken from ani-
mals sacrificed at nine months of age. As shown in Table
2, the splenocyte number in NZB/W mice given vehicle
was significantly (P  0.05) higher than normal CD-1
mice at comparable age. MMF and combined therapy
significantly (P  0.05) reduced the cell count near to
control values. The splenocyte number in mice given
DFU was lower than in vehicle-treated group; however,
the difference did not reach statistical significance.
As for the lymphocyte subset analysis, no differences
were recorded among groups in the percentage of B cells,
CD4 cells, CD8 cells and the ratio of CD4:CD8.
Effect of MMF, COX-2 inhibitor, and their
combination on splenocyte TXB2 release
Since TXA2 has been implicated as a mediator of lym-
phocyte proliferation and activation [36], we further ex-
amined whether splenocytes from NZB/W mice pro-
duced higher than normal amounts of this eicosanoid.
To this purpose, aliquots (1  106 cells/mL) of freshly
isolated splenocytes from NZB/W mice were incubated
for 60 minutes at 37C in RPMI without FCS for the
assessment of TXB2 in the supernatant. The production
of TXB2 by splenocytes from NZB/W mice given vehicle
was significantly higher than that from CD-1 mice
(230.97  13.16 vs. 53.33  13.39 pg/106 cells, P  0.05).
Chronic treatment with either MMF or DFU as well as
their combination significantly (P  0.05) reduced TXB2
levels to values not different from those found in normal
CD-1 mice (MMF, 86.14  14.79 pg/106 cells; DFU,
114.15  22.43 pg/106 cells; combined therapy, 87.08 
10.75 pg/106 cells).
DISCUSSION
The present study shows that in NZB/W mice, treat-
ment with MMF begun after the onset of immune com- Fig. 6. Effects of chronic treatment with the COX-2 inhibitor DFU
( ) or vehicle () on renal eicosanoid production in NZB/W lupusplex deposition [1, 32, 33] significantly prevented renal
mice. Measurements were performed in kidney homogenate taken atfunction impairment and limited glomerular hypercellu-
nine months of age. Treatment started at five months. Values are ex-
larity and tubulointerstitial damage. MMF also delayed pressed as mean  SE. *P  0.05 vs. control (2-month-old NZB/W);
P  0.05 vs. vehicle.the onset of proteinuria and ameliorated animal survival
as compared with vehicle-treated mice, but the differ-
ences were not statistically significant. Previous data
showed that MMF was an effective preventive measure
in NZB/W lupus mice [14]. The present findings extend
those results and show that when given to animals with
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Fig. 7. Urinary excretion of eicosanoids in NZB/W mice given DFU ( ) or vehicle () since five months of age. Values are expressed as mean 
SE. *P  0.05 vs. two and five months; P  0.05 vs. vehicle at the same time.
Table 2. Splenocyte count and lymphocyte subset distribution in NZB/W-treated mice and CD-1 mice at 9 months of age
B cells CD4 cells CD8 cells
Total splenocytes
Groups 10 6 % CD4:CD8 ratio
NZB/W
Vehicle 121.622.4a 41.710.9 23.61.7 8.51.6 2.80.5
MMF 73.621.7b 39.510.7 23.03.4 12.24.8 2.31.4
DFU 96.117.6 44.91.9 21.80.68 8.32.0 2.70.7
MMF  DFU 72.714.8b 42.93.1 22.481.9 11.51.9 1.90.4
CD-1 69.08.7 43.47.0 21.94.9 8.43.2 2.60.5
Results are means  SE. Abbreviations are in Table 1.
a P  0.05 vs. CD-1
b P  0.05 vs. NZB/W given vehicle
established disease, therapy with MMF was also effec- NZB/W mice with overt disease, which confirmed previ-
ous evidence in experimental and human lupus nephritistive, although, as expected, the effect of the preventive
regimen was more impressive. In another model of lupus [18, 19]. Moreover, the exaggerated renal synthesis of
TXB2 probably derives from COX-2, as documented bynephritis, the MRL/lpr mouse, Van Bruggen et al docu-
mented that early but not late treatment with MMF increased transcript levels of COX-2 but not COX-1
mRNA in the kidneys of nine-month-old NZB/W mice.prevented the development of glomerulonephritis, as ev-
idenced by the delayed onset of albuminuria, the signifi- We found that the DFU treatment remarkably afforded
preservation of renal function and structural injury.cant reduction of glomerular IgG and complement C3
deposition, and the diminution of glomerular inflamma- However, it displayed only a partial effect on proteinuria
and animal survival. COX-2 inhibitor was effective intion [15]. In small studies in patients with proliferative
lupus nephritis resistant to cyclophosphamide, combined reducing the exaggerated renal TXB2 synthesis while
leaving vasodilatory prostaglandin generation essentiallyMMF/prednisone therapy appeared to be effective in
controlling renal disease [37, 38]. Very recently, Chan et unaltered. This effect could be advantageous if one con-
siders that in patients with lupus nephritis renal functional’s study in 42 patients with proliferative lupus nephritis,
who were treated with prednisolone and MMF or with critically depends on vasodilatory prostaglandins, and
that the nonselective inhibition of the prostaglandin-prednisolone and cyclophosphamide followed by azathi-
oprine, found that treatment with MMF was as effective forming enzyme COXs with conventional nonsteroidal
anti-inflammatory compounds can be detrimental on re-as and had fewer side effects than sequential treatment
of cyclophosphamide and azathioprine [39]. nal hemodynamics in these patients [19, 40].
Our finding that the protective effect of MMF or DFUNext, the effect of the COX-2 inhibitor DFU was
assessed in NZB/W mice. The rationale of using the therapeutic regimens was only partial in lupus mice was
instrumental to studying whether their combinationCOX-2 blocker was offered by findings presented here of
an increased production of TXB2 in kidney homogenate would result in more renoprotection. Actually, combin-
ing MMF with DFU greatly improved the survival oftogether with increased urinary excretion of TXB2 in
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NZB/W mice to the point that 60% of animals were partly, by its ability to interfere with the localization
of immune complexes in the glomerular capillary wall.alive at 13 months of age, while all animals given vehicle
or the COX-2 inhibitor died and only 20% of those Specifically, because MMF is able to inhibit synthesis of
fucose- and mannose-containing saccharide componentstreated with MMF survived. The combination dramati-
cally retarded the onset of proteinuria. Thus, at nine of membrane glycoproteins [7], it was concluded that
altered glycosylation of membrane proteins might inducemonths, only 13% of mice on MMF plus DFU treatment
developed proteinuria versus 60 and 58% proteinuric changes of GBM characteristics, resulting in decreased
binding of immune complexes [15].mice in the groups given MMF and DFU alone. Com-
bined therapy afforded greater protection against renal In conclusion, we document the therapeutic effect of
the combined MMF and COX-2 inhibitor treatment infunction deterioration than the individual drugs. It also
limited glomerular and tubulointerstitial damage and re- ameliorating renal manifestation of the disease and pro-
longing survival in NZB/W lupus mice with establishedduced IgG and C3 deposits in the glomerular capillary
wall to a greater extent than either MMF or DFU alone. renal disease. These results imply that future studies
in humans should be designed to assess whether MMFWe tried to explain whether the favorable effects of the
drug combination on the kidney and animal survival combined with COX-2 inhibitors can be an effective
treatment of lupus nephritis, with the obvious advantagewere attributable to an immune modulatory action on B
and T cells. In our experiments, signs of T-cell activation of avoiding steroid-related toxicity.
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